2,3,6,7-Tetrahydro-5(1H)-indolizinon | 69956-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,3,6,7-Tetrahydro-5(1H)-indolizinon
• 英文别名: 2,3,6,7-tetrahydro-1H-indolizin-5-one；2,3,6,7-tetrahydro-1H-indolizin-5-one
• CAS: 69956-34-9
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: APVLVICDUHUHBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,4,4a,5,6,7-hexahydro-2H-cyclopentapyridine 、 乙酸乙酯 、 氧气 以22%的产率得到
  参考文献：
  名称：

  SCHUMANN D.; NAUMANN A.; WIRTZ K.-P., CHEM. BER., 1979, 112, NO 2, 734-742

  摘要：

  DOI：

文献信息

• [EN] PROTEIN KINASE C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE KINASE C ET UTILISATIONS DE CEUX-CI
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2013152198A1

  公开（公告）日：2013-10-10

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  这份披露涉及一些化合物，这些化合物可用作蛋白激酶C（PKC）的抑制剂，因此可用于治疗通过PKC的活性介导或维持的各种疾病和紊乱。这份披露还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• CINNAMIDE COMPOUND
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1757591A1

  公开（公告）日：2007-02-28

  The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) -C≡C- or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

  本发明涉及一种由式（I）表示的化合物： (其中Ar1代表可被1至3个取代基取代的咪唑基；Ar2代表可被1至3个取代基取代的吡啶基、嘧啶基或苯基；X1代表(1)-C≡C-或(2)可被取代的双键等；R1和R2代表例如可被取代的C1-6烷基或C3-8环烷基）或其药理学上可接受的盐，以及其作为药剂的用途。
• BICYCLIC CINNAMIDE COMPOUND
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1953158A1

  公开（公告）日：2008-08-06

  A bicyclic cinnamide compound represented by the general formula (I): wherein ---- represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group optionally substituted by one to three substituents; R1 and R2 each represents a C1-6 alkyl group, a hydroxyl group, etc.; Z1 represents an optionally substituted methylene group or vinylene group, an oxygen atom, or an imino group optionally substituted by a Cl-6 alkyl group or a Cl-6 acyl group; and p, q, and r each is an integer of 0 to 2. It functions to reduce Aβ40 and Aβ42. It is hence useful especially as a prevention or remedy for neurodegenerative diseases of which Aβ is causative, such as Alzheimer's disease and Down's syndrome.

  由通式(I)代表的双环肉桂化合物： 其中 ---- 代表单键或双键；Ar1 代表任选被一至三个取代基取代的苯基或吡啶基；R1 和 R2 分别代表 C1-6 烷基、羟基等；Z1 代表任选被取代的亚甲基或亚乙烯基、氧原子或任选被 Cl-6 烷基或 Cl-6 丙烯酸基取代的亚氨基；p、q 和 r 分别为 0 至 2 的整数。 它具有降低 Aβ40 和 Aβ42 的功能。因此，它特别适用于预防或治疗 Aβ 导致的神经退行性疾病，如阿尔茨海默氏症和唐氏综合症。
• IMMUNOSTIMULATING SWAINSONINE ANALOGS
  申请人：TORONTO RESEARCH CHEMICALS INC.

  公开号：EP0613478A1

  公开（公告）日：1994-09-07
• PROTEIN KINASE C INHIBITORS AND USES THEREOF
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2833889A1

  公开（公告）日：2015-02-11